The DiscovEHR study, conducted by the Regeneron Genetics Center and the Geisinger Health System, uncovered many associations between genetic variants and clinical phenotypes.
The Children's National team will return diagnostic results to patients and Regeneron will use the genomic data in its drug development pipeline.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
Mount Sinai is the latest healthcare provider to link up with Regeneron's Genetics Center, to pair NGS data with electronic medical record data.
In the study, the partners will perform exome sequencing and whole-genome array genotyping on more than 9,000 individuals with diabetes or with diabetic relatives.
Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.
Geisinger Health System's MyCode Community Health Initiative has signed up more than 100,000 participants and has returned results to about 100 patients.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
Independent research groups garnered evidence that mutations to the ANGPTL4 gene can lower blood triglyceride levels and reduce coronary artery disease risk.
ERS Genomics was founded to provide broad access to CRISPR-Cas9 intellectual property, which is based on the research of Emmanuelle Charpentier.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.